Halozyme Therapeutics (HALO) Misses Q3 EPS by 2c
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $103.00 --0%
Financial Fact:
Net income (loss): -28.95M
Today's EPS Names:
ELWT, CAAP, RNW, More
Financial Fact:
Net income (loss): -28.95M
Today's EPS Names:
ELWT, CAAP, RNW, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q3 EPS of ($0.16), $0.02 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $14.6 million versus the consensus estimate of $16.5 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla to launch Cybercab in Austin this month - report
- XP Inc. (XP) Tops Q2 EPS by 8c
- iQIYI (IQ) Misses Q2 EPS by 21c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
